AbbVie (NYSE:ABBV) Issues Q2 2026 Earnings Guidance

AbbVie (NYSE:ABBV) issued an update on its second quarter 2026 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 3.570-3.610 for the period, compared to the consensus estimate of 3.770. The company issued revenue guidance of -. AbbVie also updated its FY 2026 guidance to 13.910-14.110 EPS.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Evercore set a $235.00 price target on AbbVie in a research report on Friday, May 15th. DZ Bank raised AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Thursday, April 30th. Guggenheim restated a “buy” rating and set a $249.00 target price on shares of AbbVie in a report on Friday, May 1st. Morgan Stanley raised their price target on AbbVie from $270.00 to $278.00 and gave the stock an “overweight” rating in a research note on Thursday, April 30th. Finally, Cantor Fitzgerald lifted their price target on shares of AbbVie from $240.00 to $265.00 and gave the company an “overweight” rating in a report on Monday. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $256.67.

AbbVie Stock Performance

Shares of NYSE ABBV traded up $3.40 during mid-day trading on Tuesday, hitting $258.15. 643,155 shares of the stock traded hands, compared to its average volume of 7,167,084. The company has a market cap of $456.11 billion, a price-to-earnings ratio of 127.43, a PEG ratio of 0.86 and a beta of 0.30. The stock has a fifty day moving average price of $221.27 and a 200-day moving average price of $220.47. AbbVie has a 52 week low of $184.63 and a 52 week high of $261.64.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, topping the consensus estimate of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The business had revenue of $15 billion for the quarter, compared to analyst estimates of $14.72 billion. During the same quarter in the previous year, the firm posted $2.46 earnings per share. AbbVie’s quarterly revenue was up 12.4% on a year-over-year basis. As a group, sell-side analysts predict that AbbVie will post 14.28 EPS for the current fiscal year.

AbbVie Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th will be paid a $1.73 dividend. The ex-dividend date is Wednesday, July 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.7%. AbbVie’s payout ratio is currently 340.89%.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie received a European Commission approval for TEPKINLY (epcoritamab) plus lenalidomide and rituximab to treat relapsed or refractory follicular lymphoma. The approval expands the drug’s reach in Europe and supports AbbVie’s oncology growth story. Article: AbbVie Announces TEPKINLY approval by the European Commission
• Positive Sentiment: Cantor Fitzgerald raised its price target on AbbVie to $265 and kept an overweight rating, signaling continued analyst confidence in the stock’s upside. Article: AbbVie price target raised by Cantor Fitzgerald
• Neutral Sentiment: AbbVie is also getting some investor focus ahead of its upcoming quarterly report, with analysts watching whether Skyrizi and Rinvoq can offset continued pressure from Humira declines. Article: Will Immunology Franchise Aid AbbVie’s Upcoming Q2 Results?
• Negative Sentiment: AbbVie cut its second-quarter 2026 EPS guidance to $3.57-$3.61, below the consensus estimate of $3.77, which could pressure shares. FY 2026 EPS guidance was also lowered to $13.91-$14.11 versus the Street’s $14.25 forecast.

Institutional Investors Weigh In On AbbVie

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. T. Rowe Price Investment Management Inc. boosted its stake in shares of AbbVie by 38.0% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 25,847 shares of the company’s stock worth $5,906,000 after acquiring an additional 7,116 shares during the last quarter. Strive Financial Group LLC bought a new stake in shares of AbbVie during the 4th quarter valued at $216,000. Blue Sparrow LLC DE purchased a new stake in shares of AbbVie in the 4th quarter worth $28,561,000. Mercer Global Advisors Inc. ADV increased its stake in shares of AbbVie by 5.9% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 430,631 shares of the company’s stock worth $100,411,000 after purchasing an additional 23,859 shares in the last quarter. Finally, Summit Global Investments raised its holdings in AbbVie by 21.4% in the 4th quarter. Summit Global Investments now owns 16,916 shares of the company’s stock worth $3,865,000 after purchasing an additional 2,987 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.